Immune checkpoint inhibition by anti‐PDCD1 (anti‐PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2018-11, Vol.183 (4), p.674-678
Hauptverfasser:	Qiu, Yushi, Li, Zhimin, Pouzoulet, Frederic, Vishnu, Prakash, Copland, John A., Knutson, Keith L., Soussain, Carole, Tun, Han W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents, Immunological - pharmacology anti‐PDCD1 (anti‐PD1) CD274 (PD‐L1) Central nervous system Central Nervous System Neoplasms - drug therapy Central Nervous System Neoplasms - immunology Central Nervous System Neoplasms - pathology Hematology Humans Lymphoma Lymphoma - drug therapy Lymphoma - immunology Lymphoma - pathology Mice Monoclonal antibodies Neoplasm Proteins - antagonists & inhibitors Neoplasm Proteins - immunology Neoplasms, Experimental - drug therapy Neoplasms, Experimental - immunology Neoplasms, Experimental - pathology PD-1 protein PDCD1LG2 (PD‐L2) primary central nervous system lymphoma (PCNSL) Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!